ARTL
Price
$0.96
Change
+$0.01 (+1.05%)
Updated
May 22, 04:43 PM (EDT)
Capitalization
3.13M
76 days until earnings call
LSTA
Price
$2.51
Change
+$0.01 (+0.40%)
Updated
May 22, 04:48 PM (EDT)
Capitalization
21.93M
88 days until earnings call
Interact to see
Advertisement

ARTL vs LSTA

Header iconARTL vs LSTA Comparison
Open Charts ARTL vs LSTABanner chart's image
Artelo Biosciences
Price$0.96
Change+$0.01 (+1.05%)
Volume$1K
Capitalization3.13M
Lisata Therapeutics
Price$2.51
Change+$0.01 (+0.40%)
Volume$121
Capitalization21.93M
ARTL vs LSTA Comparison Chart
Loading...
ARTL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LSTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARTL vs. LSTA commentary
May 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARTL is a Hold and LSTA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 23, 2025
Stock price -- (ARTL: $0.95 vs. LSTA: $2.50)
Brand notoriety: ARTL and LSTA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARTL: 3% vs. LSTA: 151%
Market capitalization -- ARTL: $3.13M vs. LSTA: $21.93M
ARTL [@Biotechnology] is valued at $3.13M. LSTA’s [@Biotechnology] market capitalization is $21.93M. The market cap for tickers in the [@Biotechnology] industry ranges from $305.18B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARTL’s FA Score shows that 0 FA rating(s) are green whileLSTA’s FA Score has 1 green FA rating(s).

  • ARTL’s FA Score: 0 green, 5 red.
  • LSTA’s FA Score: 1 green, 4 red.
According to our system of comparison, both ARTL and LSTA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARTL’s TA Score shows that 4 TA indicator(s) are bullish while LSTA’s TA Score has 6 bullish TA indicator(s).

  • ARTL’s TA Score: 4 bullish, 4 bearish.
  • LSTA’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, LSTA is a better buy in the short-term than ARTL.

Price Growth

ARTL (@Biotechnology) experienced а -4.25% price change this week, while LSTA (@Biotechnology) price change was +14.68% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.82%. For the same industry, the average monthly price growth was +7.45%, and the average quarterly price growth was -1.67%.

Reported Earning Dates

ARTL is expected to report earnings on Aug 06, 2025.

LSTA is expected to report earnings on Aug 18, 2025.

Industries' Descriptions

@Biotechnology (+4.82% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LSTA($21.9M) has a higher market cap than ARTL($3.13M). ARTL YTD gains are higher at: -10.123 vs. LSTA (-16.107). ARTL has higher annual earnings (EBITDA): -10.11M vs. LSTA (-22.24M). LSTA has more cash in the bank: 31.2M vs. ARTL (2.34M). ARTL has less debt than LSTA: ARTL (104K) vs LSTA (137K). LSTA has higher revenues than ARTL: LSTA (1M) vs ARTL (0).
ARTLLSTAARTL / LSTA
Capitalization3.13M21.9M14%
EBITDA-10.11M-22.24M45%
Gain YTD-10.123-16.10763%
P/E RatioN/AN/A-
Revenue01M-
Total Cash2.34M31.2M7%
Total Debt104K137K76%
FUNDAMENTALS RATINGS
ARTL vs LSTA: Fundamental Ratings
ARTL
LSTA
OUTLOOK RATING
1..100
7712
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
24
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6352
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LSTA's Valuation (24) in the null industry is in the same range as ARTL (50). This means that LSTA’s stock grew similarly to ARTL’s over the last 12 months.

LSTA's Profit vs Risk Rating (100) in the null industry is in the same range as ARTL (100). This means that LSTA’s stock grew similarly to ARTL’s over the last 12 months.

LSTA's SMR Rating (100) in the null industry is in the same range as ARTL (100). This means that LSTA’s stock grew similarly to ARTL’s over the last 12 months.

LSTA's Price Growth Rating (52) in the null industry is in the same range as ARTL (63). This means that LSTA’s stock grew similarly to ARTL’s over the last 12 months.

LSTA's P/E Growth Rating (100) in the null industry is in the same range as ARTL (100). This means that LSTA’s stock grew similarly to ARTL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARTLLSTA
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
82%
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
76%
MACD
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
75%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 18 days ago
79%
Bullish Trend 7 days ago
78%
Declines
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 2 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
86%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
68%
View a ticker or compare two or three
Interact to see
Advertisement
ARTL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LSTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VIVK0.780.01
+1.56%
Vivakor
BVN14.930.12
+0.81%
Compania de Minas Buenaventura SA
THRD5.18-0.02
-0.38%
Third Harmonic Bio
WEC106.54-1.03
-0.96%
WEC Energy Group
GYRE10.37-1.03
-9.04%
Gyre Therapeutics

LSTA and

Correlation & Price change

A.I.dvisor tells us that LSTA and RAIN have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LSTA and RAIN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LSTA
1D Price
Change %
LSTA100%
-1.96%
RAIN - LSTA
29%
Poorly correlated
-21.34%
NAGE - LSTA
26%
Poorly correlated
-5.86%
GMAB - LSTA
26%
Poorly correlated
+0.93%
ASND - LSTA
26%
Poorly correlated
-2.15%
MRUS - LSTA
25%
Poorly correlated
-1.82%
More